Bloomberg has an extensive article today on Takeda's leading effort to develop a norovirus--or vomiting bug--vaccine that could prove a boon to the cruise ships and schools which are often afflicted with outbreaks. Every year about 21 million people in the U.S. are infected, and about 800 die. This experimental vaccine combines components of two types of norovirus, which Takeda believes should provide an effective guard against all the viral strains in circulation. And some analysts believe it could be worth up to $400 million a year in revenue if Takeda can get an approval ahead of its rivals. Story | More from FierceVaccines